GlobeNewswire

Skybox Security Suite 10 Simplifies Cyber Risk Management

Del

Skybox 10 introduces industry-leading prioritization techniques to score risk of vulnerabilities and assets, enhances security policy management automation and further improves user experience

SAN JOSE, Calif., June 11, 2019 (GLOBE NEWSWIRE) -- Skybox® Security, a global leader in cyber risk management, has announced the launch of Skybox® Security Suite 10. This latest product version further strengthens Skybox capabilities to simplify enterprise security management processes that oversee mass-scale, hybrid networks.

“The CISO’s biggest challenge is complexity,” said Skybox CEO and founder Gidi Cohen. “It has become impossible for security teams to understand — let alone manage — security effectively in today’s multi-cloud, hybrid environments. The development behind Skybox 10 was done with the aim of making it easier to manage security policies in clouds, monitor risks to industrial control systems, and find important assets at risk. We want to help CISOs maximize the value of their teams and their technology to secure and support the business.”

Skybox 10 brings an intuitive, customizable user experience to simplify management of vulnerabilities, security policies, firewalls and changes from a central solution. Cloud and operational technology (OT) security insights are integrated seamlessly for uniform risk management across hybrid networks. Intelligent automation brings harmony and efficiency to multi-vendor environments, integrating data and yielding contextual insight. Customers can also use the new REST API to leverage Skybox intelligence in other tools and processes, increasing their ROI.

Skybox 10 also includes several new integrations including Splunk, ElasticSearch and ServiceNow, as well as Twistlock which provides visibility to the security of containers in cloud-native applications.

The biggest changes are found in the vulnerability management module, Skybox® Vulnerability Control, which just received Best Vulnerability Management Solution at the SC Europe Awards. The new release provides fast access to vulnerability insights through fully customizable dashboards and reports. New, flexible risk scoring allows users to replace generic severity scores with context-based scores unique to their environment; this prioritization method shrinks the workload to focus on exposed and exploitable vulnerabilities — typically less than one percent of an organization’s occurrences.

“Risk scoring is one of those things that’s so simple on its face, but in reality, there’s a hugely detailed process going on under the hood,” said Skybox Security VP of Products Amrit Williams. “Our methodology goes way beyond CVSS severity and exploitability, taking into account asset importance, exposure within the network and more. We make it easy to determine which assets are at risk and see if an existing security control can be used to protect against an attack, even without a patch. This is critical to knowing which risks require immediate attention and which ones can wait for scheduled remediation.”

“For the last decade, accurate risk prioritization has been the thing that eludes enterprises and can lead to serious damage,” said Michael Osterman, principal analyst at Osterman Research. “Having a way to bring the right vulnerabilities — and vulnerable assets — to light with an approach that quantifies exposure and exploitability will be hugely valuable.”

To learn more about Skybox 10, visit our webpage.

About Skybox Security

www.skyboxsecurity.com

Skybox provides the industry’s broadest cybersecurity management platform to address security challenges within large, complex networks. By integrating with more than 130 networking and security technologies, the Skybox® Security Suite provides comprehensive attack surface visibility and the context needed for informed action. Our analytics, automation and intelligence improve the efficiency and performance of security operations in vulnerability and threat management and firewall and security policy management for the world’s largest organizations.

© 2019 Skybox Security, Inc. All rights reserved. Skybox Security and the Skybox Security logo are either registered trademarks or trademarks of Skybox Security, Inc., in the United States and/or other countries. All other trademarks are the property of their respective owners. Product specifications subject to change at any time without prior notice.

Tweet This: .@SkyboxSecurity launches #Skybox10 with new #riskscoring techniques for #vulnerabilities, assets and groups, enhanced #securitypolicy management automation, and new integration for #cloud and #OT http://ow.ly/scG030oUZDu

PR CONTACT INFORMATION

Victoria Davis Schmidt
Corporate Communications for Skybox Security
+1 571 340 0181 | Victoria.Schmidt@skyboxsecurity.com

Allison + Partners for Skybox Security
United Kingdom: Daniel Couzens
+44 (0)20 7437 0227 | danielc@allisonpr.com

Germany: Stephanie Thoma
+49 (0)89 388 892 012| stephaniet@allisonpr.com

France: Xavier Delhôme
+33 1 41 31 75 09 | xavierd@allisonpr.com

Alliance Public Relations Pvt. Ltd.
India: Meenakshi Lenka
+91-9810577773 | meenakshi@proalliancepr.com

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle

iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CESTPressemelding

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CESTPressemelding

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad

Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CESTPressemelding

Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi